Asthma
Oral Dexpramipexole.
Our Novel Candidate for
Eosinophilic Asthma
An Uncommon Approach to a Common
Respiratory Disorder
Dexpramipexole
Eosinophils & Asthma How Do They Relate?

50%
of all patients suffering with severe asthma have elevated numbers of eosinophils in their blood and lungs.

High levels of eosinophils increase the risk of asthma attacks and lung damage.

At present, the only treatments for eosinophilic asthma come in the form of injections or infusions.

Dexpramipexole is an experimental drug shown to block eosinophils from maturing in the bone marrow, and is under investigation as a potential treatment for eosinophilic asthma.

Ongoing clinical research on the role of eosinophils in asthma has already created benefits for many patients.
Our Goal is to demonstrate the safety and effectiveness of dexpramipexole
Phase 2 trial data will be reported soon. We welcome you to follow our progress.
Latest Publications about Dexpramipexole
Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 demonstrating that oral dexpramipexole improves airflow obstruction as measured by forced expiry volume (FEV1), largely through its effect on forced vital capacity (FVC)
Discover this News
10.08.2021Phase 2 Trial Evaluating the Effect of Dexpramipexole on Eosinophil Biomarkers and Lung Function in Asthma
Discover this News
09.07.2021Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating that Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung Function
Discover this News
05.17.2021Knopp Biosciences Reports Positive Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021
Discover this News
05.13.2021Knopp Biosciences to Present Details of Positive Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021
Discover this News
01.14.2021Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma
Discover this News
09.16.2020Knopp Biosciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic Asthma
Discover this News
12.02.2019Knopp Biosciences and University of Leicester Announce Update on Planned Phase 2 Clinical Trial of Oral Dexpramipexole in Severe Eosinophilic Asthma
Discover this News
07.09.2019Knopp Biosciences to Present Clinical Data for Dexpramipexole at 11th Biennial Symposium of the International Eosinophil Society
Discover this News
04.24.2019Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole for Treatment of Hypereosinophilic Syndrome
Discover this News